These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15339046)

  • 1. Role of subtilisin-like convertases in cadherin processing or the conundrum to stall cadherin function by convertase inhibitors in cancer therapy.
    Müller EJ; Caldelari R; Posthaus H
    J Mol Histol; 2004 Mar; 35(3):263-75. PubMed ID: 15339046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase inhibition: Paralyzing the cell's master switches.
    Klein-Szanto AJ; Bassi DE
    Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel insights into cadherin processing by subtilisin-like convertases.
    Posthaus H; Dubois CM; Müller E
    FEBS Lett; 2003 Feb; 536(1-3):203-8. PubMed ID: 12586364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.
    Khatib AM; Siegfried G; Chrétien M; Metrakos P; Seidah NG
    Am J Pathol; 2002 Jun; 160(6):1921-35. PubMed ID: 12057895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of proprotein convertases.
    Basak A
    J Mol Med (Berl); 2005 Nov; 83(11):844-55. PubMed ID: 16215768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.
    Pokharel Y; Virani SS; Ballantyne CM
    Curr Atheroscler Rep; 2015 May; 17(5):508. PubMed ID: 25782778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertases: Key players in inflammation-related malignancies and metastasis.
    Siegfried G; Descarpentrie J; Evrard S; Khatib AM
    Cancer Lett; 2020 Mar; 473():50-61. PubMed ID: 31899298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases.
    Bontemps Y; Scamuffa N; Calvo F; Khatib AM
    Med Res Rev; 2007 Sep; 27(5):631-48. PubMed ID: 17019676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential anti-tumorigenic and anti-metastatic side of the proprotein convertases inhibitors.
    Lahlil R; Calvo F; Khatib AM
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):83-91. PubMed ID: 19149690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertases: "master switches" in the regulation of tumor growth and progression.
    Bassi DE; Fu J; Lopez de Cicco R; Klein-Szanto AJ
    Mol Carcinog; 2005 Nov; 44(3):151-61. PubMed ID: 16167351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertases as therapeutic targets.
    Chrétien M; Seidah NG; Basak A; Mbikay M
    Expert Opin Ther Targets; 2008 Oct; 12(10):1289-300. PubMed ID: 18781827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase inhibitory activities of flavonoids isolated from Oroxylum indicum.
    Majumdar S; Mohanta BC; Chowdhury DR; Banik R; Dinda B; Basak A
    Curr Med Chem; 2010; 17(19):2049-58. PubMed ID: 20423311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertases: lessons from knockouts.
    Scamuffa N; Calvo F; Chrétien M; Seidah NG; Khatib AM
    FASEB J; 2006 Oct; 20(12):1954-63. PubMed ID: 17012247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proprotein convertases are potential targets in the treatment of dyslipidemia.
    Seidah NG; Prat A
    J Mol Med (Berl); 2007 Jul; 85(7):685-96. PubMed ID: 17351764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enediynyl peptides and iso-coumarinyl methyl sulfones as inhibitors of proprotein convertases PCSK8/SKI-1/S1P and PCSK4/PC4: Design, synthesis and biological evaluations.
    Basak A; Goswami M; Rajkumar A; Mitra T; Majumdar S; O'Reilly P; Bdour HM; Trudeau VL; Basak A
    Bioorg Med Chem Lett; 2015; 25(10):2225-37. PubMed ID: 25881830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proprotein convertases furin and PACE4 play a significant role in tumor progression.
    Bassi DE; Mahloogi H; Klein-Szanto AJ
    Mol Carcinog; 2000 Jun; 28(2):63-9. PubMed ID: 10900462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.
    Bryan RT
    Philos Trans R Soc Lond B Biol Sci; 2015 Feb; 370(1661):20140042. PubMed ID: 25533099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Processing of pro-thrombostasin by a recombinant subtilisin-like proprotein convertase derived from the salivary glands of horn flies (Haematobia irritans).
    Zhang D; Cupp MS; Cupp EW
    Insect Biochem Mol Biol; 2004 Dec; 34(12):1289-95. PubMed ID: 15544942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.